Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Quidel Corporation (QDEL : NSDQ)
 
 • Company Description   
Quidel Corporation is in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company sells its products directly to end users and distributors for professional use. Quidel operates in business segments that develop, manufacture and market it in 4 product segments. Rapid Immunoassay - Category includes the Sofia and Sofia 2 Analyzers, QuickVue, InflammaDry and AdenoPlus. Cardiometabolic Immunoassay - Category includes the Triage MeterPro, a portable testing platform that runs a comprehensive menu of tests via the rapid diagnosis of critical diseases and health conditions, as well as detection of certain drugs of abuse. Molecular Diagnostic Solutions: This category includes the Lyra, Solana and Savanna systems. Lyra Molecular Real-Time Polymerase Chain Reaction assays provide important benefits to the customer. Specialized Diagnostic Solutions - This category includes Virology and Specialty Products. Virology product category includes the FDA-cleared bioassay, Thyretain.

Number of Employees: 1,600

 
 • Price / Volume Information   
Yesterday's Closing Price: $100.60 Daily Weekly Monthly
20 Day Moving Average: 575,245 shares
Shares Outstanding: 41.85 (millions)
Market Capitalization: $4,209.94 (millions)
Beta: 0.02
52 Week High: $180.06
52 Week Low: $88.05
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.32% -1.01%
12 Week 2.82% 11.13%
Year To Date -25.48% -11.73%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9975 SUMMERS RIDGE ROAD
-
SAN DIEGO,CA 92121
USA
ph: 858-552-1100
fax: 858-453-4338
rargueta@quidel.com http://www.quidel.com
 
 • General Corporate Information   
Officers
Douglas C. Bryant - Chief Executive Officer and President
Kenneth F. Buechler - Chairman of the Board
Randall J. Steward - Chief Financial Officer
Edward L. Michael - Director
Kathy P. Ordonez - Director

Peer Information
Quidel Corporation (BJCT)
Quidel Corporation (CADMQ)
Quidel Corporation (APNO)
Quidel Corporation (UPDC)
Quidel Corporation (IMTIQ)
Quidel Corporation (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 74838J101
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 41.85
Most Recent Split Date: (:1)
Beta: 0.02
Market Capitalization: $4,209.94 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $3.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $16.30 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 6.17
Trailing 12 Months: 4.09
PEG Ratio: -
Price Ratios
Price/Book: 1.74
Price/Cash Flow: 5.25
Price / Sales: 1.81
EPS Growth
vs. Year Ago Period: 170.02%
vs. Previous Quarter: 60.81%
Sales Growth
vs. Year Ago Period: 167.03%
vs. Previous Quarter: 57.37%
ROE
03/31/22 - 56.46
12/31/21 - 45.78
09/30/21 - 62.24
ROA
03/31/22 - 44.21
12/31/21 - 35.06
09/30/21 - 46.33
Current Ratio
03/31/22 - 4.29
12/31/21 - 4.45
09/30/21 - 3.87
Quick Ratio
03/31/22 - 3.92
12/31/21 - 3.84
09/30/21 - 3.20
Operating Margin
03/31/22 - 44.85
12/31/21 - 43.56
09/30/21 - 48.80
Net Margin
03/31/22 - 43.26
12/31/21 - 41.46
09/30/21 - 47.20
Pre-Tax Margin
03/31/22 - 55.87
12/31/21 - 53.01
09/30/21 - 60.96
Book Value
03/31/22 - 57.71
12/31/21 - 46.30
09/30/21 - 39.21
Inventory Turnover
03/31/22 - 3.10
12/31/21 - 2.17
09/30/21 - 2.20
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©